Opinion|Videos|August 6, 2024
Updates in CLL Treatment Strategies with Noncovalent BTKis
Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on the recent FDA approval of pirtobrutinib in patients with CLL who have received at least 2 prior lines of therapy, and briefly highlight key data from BRUIN that led to this approval.
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5